Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein - PubMed (original) (raw)
. 1997 Oct 24;272(43):27444-9.
doi: 10.1074/jbc.272.43.27444.
Affiliations
- PMID: 9341197
- DOI: 10.1074/jbc.272.43.27444
Free article
Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein
Y Takagi et al. J Biol Chem. 1997.
Free article
Abstract
Elongin C is a 112-amino acid protein that is found in mammalian cells as a positive regulatory subunit of heterotrimeric RNA polymerase II elongation factor Elongin (SIII) and as a component of a multiprotein complex containing the von Hippel-Lindau (VHL) tumor suppressor protein. As a subunit of the Elongin complex, Elongin C interacts directly with the transcriptionally active Elongin A subunit and potently induces its elongation activity; in addition, Elongin C interacts with the ubiquitin-like Elongin B subunit, which regulates the interaction of Elongin C with Elongin A. As a component of the VHL complex, Elongin C interacts directly with both Elongin B and the VHL protein. Binding of the VHL protein to Elongin C was found to prevent Elongin C from interacting with and activating Elongin A in vitro, leading to the proposal that one function of the VHL protein may be to regulate RNA polymerase II elongation by negatively regulating the Elongin complex. In this report, we identify Elongin C sequences required for its interaction with the VHL protein. We previously demonstrated that the ability of Elongin C to bind and activate Elongin A is sensitive to mutations in the C-terminal half of Elongin C, as well as to mutations in an N-terminal Elongin C region needed for formation of the Elongin BC complex. Here we show that interaction of Elongin C with the VHL tumor suppressor protein depends strongly on sequences in the C terminus of Elongin C but is independent of the N-terminal Elongin C region required for binding to Elongin B and for binding and activation of Elongin A. Taken together, our results are consistent with the proposal that the VHL protein negatively regulates Elongin C activation of the Elongin complex by sterically blocking the interaction of C-terminal Elongin C sequences with Elongin A. In addition, our finding that only a subset of Elongin C sequences required for its interaction with Elongin A are critical for binding to VHL may offer the opportunity to develop reagents that selectively interfere with Elongin and VHL function.
Similar articles
- Characterization of elongin C functional domains required for interaction with elongin B and activation of elongin A.
Takagi Y, Conaway RC, Conaway JW. Takagi Y, et al. J Biol Chem. 1996 Oct 11;271(41):25562-8. doi: 10.1074/jbc.271.41.25562. J Biol Chem. 1996. PMID: 8810329 - The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex.
Aso T, Haque D, Barstead RJ, Conaway RC, Conaway JW. Aso T, et al. EMBO J. 1996 Oct 15;15(20):5557-66. EMBO J. 1996. PMID: 8896449 Free PMC article. - Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C.
Botuyan MV, Koth CM, Mer G, Chakrabartty A, Conaway JW, Conaway RC, Edwards AM, Arrowsmith CH, Chazin WJ. Botuyan MV, et al. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9033-8. doi: 10.1073/pnas.96.16.9033. Proc Natl Acad Sci U S A. 1999. PMID: 10430890 Free PMC article. - The von Hippel-Lindau tumour suppressor protein: new perspectives.
Ohh M, Kaelin WG Jr. Ohh M, et al. Mol Med Today. 1999 Jun;5(6):257-63. doi: 10.1016/s1357-4310(99)01481-1. Mol Med Today. 1999. PMID: 10366821 Review. - von Hippel-Lindau tumor suppressor: not only HIF's executioner.
Czyzyk-Krzeska MF, Meller J. Czyzyk-Krzeska MF, et al. Trends Mol Med. 2004 Apr;10(4):146-9. doi: 10.1016/j.molmed.2004.02.004. Trends Mol Med. 2004. PMID: 15162797 Review.
Cited by
- The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity.
Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. Lisztwan J, et al. Genes Dev. 1999 Jul 15;13(14):1822-33. doi: 10.1101/gad.13.14.1822. Genes Dev. 1999. PMID: 10421634 Free PMC article. - Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.
DiNatale RG, Gorelick AN, Makarov V, Blum KA, Silagy AW, Freeman B, Chowell D, Marcon J, Mano R, Sanchez A, Attalla K, Weng S, Voss M, Motzer RJ, Russo P, Coleman JA, Reuter VE, Chen YB, Chan TA, Reznik E, Tickoo SK, Hakimi AA. DiNatale RG, et al. Eur Urol Focus. 2021 Mar;7(2):381-389. doi: 10.1016/j.euf.2019.11.013. Epub 2019 Dec 6. Eur Urol Focus. 2021. PMID: 31813809 Free PMC article. - Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists.
Lim DL, Ko R, Pautler SE. Lim DL, et al. Can Urol Assoc J. 2007 Jun;1(2 Suppl):S13-20. doi: 10.5489/cuaj.63. Can Urol Assoc J. 2007. PMID: 18542780 Free PMC article. - Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53.
Blanchette P, Cheng CY, Yan Q, Ketner G, Ornelles DA, Dobner T, Conaway RC, Conaway JW, Branton PE. Blanchette P, et al. Mol Cell Biol. 2004 Nov;24(21):9619-29. doi: 10.1128/MCB.24.21.9619-9629.2004. Mol Cell Biol. 2004. PMID: 15485928 Free PMC article. - Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.
Pause A, Peterson B, Schaffar G, Stearman R, Klausner RD. Pause A, et al. Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9533-8. doi: 10.1073/pnas.96.17.9533. Proc Natl Acad Sci U S A. 1999. PMID: 10449727 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials